Journal Paper Full-text Available

Effects of Alogliptin on hypertensive chronic kidney disease with Type 2 diabetes mellitus

Published in: Australasian medical journal

May 03, 2018

/ Amira Shaaban / Nadia Hussain Farideh Javaid

Background: Diabetes mellitus(DM)is a leading cause of chronic kidney disease (CKD). Theantihyperglycemic treatment options for patients with Type 2 DM are limited because of safety and tolerability concerns. Aims: To retrospectively assess the effect of using Alogliptin; a dipeptidyl peptidase-4 inhibitor (DPP-4i) alongwith conventional gliclazide: a sulphonylurea (SU) on renal outcomes and glycaemiccontrol in T2DM patients with mildCKDand hypertens...


Journal Paper

Assessing patient satisfaction with the Medication Management Review service delivered in Jordan

Published in: Journal of Pharmaceutical Health Services Research

Apr 30, 2018

/ Munther Al Najjar

Objective To investigate the effect of the Medication Management Review (MMR) service on the number of treatment‐related problems (TRPs), patient satisfaction and factors affecting patient satisfaction. Methods This prospective, randomized controlled trial was conducted at community pharmacies in Amman, Jordan. Eligible patients were randomized into active and control groups. A validated Pharmaceutical Care Manual was used for data collection and to identify TRPs for both groups. Identified TRP...


Journal Paper Full-text Available

Safety Assessment of Neoadjuvant Pertuzumab Combined with Trastuzumab in Nonmetastatic HER2-Positive Breast Cancer in Postmenopausal Elderly Women of South Asia

Published in: International Journal of Breast Cancer

Apr 19, 2018

/ Nadia Hussain / Amira Shaaban Zainab Khan

Abstract Aim. To evaluate the safety issues and adverse effects of using TCHP regimen (docetaxel, carboplatin, trastuzumab, and pertuzumab) versus TCP regimen (docetaxel, carboplatin, and trastuzumab) in older postmenopausal women with nonmetastatic HER2-positive breast cancer. HER2 overexpressed in 20–25% of breast cancer signals an aggressive form of breast cancer and is treated with trastuzumab and pertuzumab. Methods. The patient record database was accessed to identify all postmenopausal ...

Displaying 1-6 of 18 result(s).